Main business

Biomass resource regeneration Synthetic biology intelligent manufacturing

Location：

Home/Main business/Synthetic biology intelligent manufacturing

BusinessOverview1

The synthetic biology intelligent manufacturing business has the characteristics of high technology, high quality and high efficiency, and has broad prospects in the future. At present, relying on the advantages of synthetic biotechnology, Luculent Group has established an independent subsidiary and independent brand, Zhongke Langjian, to promote the research and development, production and sales of human milk oligosaccharides (HMOs) series products, and has achieved many practical results.

Breast milk oligosaccharides are a natural component of breast milk, and United States FDA (Federal Food and Drug Administration) clinical studies have proved that breastfed infants have 7 times higher immune function than non-breastfed infants, and brain development, intestinal development, and nutrient absorption capacity are better.

The human milk oligosaccharides developed and produced by Luculent using biosynthesis technology have a variety of biological activities, can effectively enhance human immunity, promote brain development, regulate intestinal flora, and ensure good health, and can be widely used in infant formula milk powder, children's milk powder, functional beverages, special medical food, health care products and other fields.

CoreBenefits

Technical advantages

By utilizing microfluidic high-throughput screening technology and AI assisted design, efficient strain construction can be achieved, and more suitable fermentation micro conditions for the strains can be screened.

cost advantage

By utilizing self-developed separation and purification technology, the processing technology and time cycle are significantly shortened, resulting in high-purity products at a lower cost.

Yield advantage

Zhongke Langjian has independently developed high-yield strains with high fermentation concentrations of tetrasaccharides and neotetrasaccharides. It is a national enterprise that has taken the lead in promoting the industrialization of tetrasaccharides and neotetrasaccharides in breast milk oligosaccharides in China.

Qualification advantages

Zhongke Langjian is the enterprise in China that has made the fastest progress in promoting the regulation of four sugar and new four sugar nutritional fortifiers.

HMOsFamilyOfProducts

Lactose-N-tetraose (LNT)

The important core structure of human milk oligosaccharides (HMOs) is composed of galactose, N-acetylglucosamine, and glucose. It has prebiotic effects, immune regulatory effects, anti-inflammatory effects, intestinal cell response regulatory effects, antibacterial activity, and antiviral activity. In the United States and the European Union, LNT has been approved for use in various foods and beverages such as infant formula, beverages, and dairy products. In addition, the EU can also apply LNT to dietary supplements, formula foods for special medical purposes, and milk based beverages or similar products intended solely for young children.

Lactose-N-tetraose (LNnT)

One of the most important neutral core HMOs, it has been certified as safe by the US FDA (GRAS) and is the second HMO approved by the National Health Commission in China to be added to infant formula after 2 '- fucosyllactose (2' - FL). LNnT has been approved for use in various foods and beverages such as infant formula, beverages, dairy products, etc. in the United States and the European Union. In addition, the EU can also apply LNnT to dietary supplements (for young children and the general population), formula foods for special medical purposes, and milk based ingredients or similar products intended solely for young children. In China, it has been approved for use in infant formula, formulated milk powder (limited to children's milk powder only), and special medical use infant formula.

ProductQualifications

2024

LNT and LNnT passed the strain safety review of the Chinese Ministry of Agriculture in January 2024

2024

LNT、LNnT于2024年1月通過中國國家農業(yè)部菌株安全審查

PlanningForTheFuture

At present, Luculent has planned to build a breast milk oligosaccharide project in Zhuhai with a production capacity of 1,000 tons/year, and is the first in China to realize the large-scale mass production of HMOs series tetrasaccharide and new tetrasaccharide products by using self-developed synthetic biology technology and high-purity glucose as raw material.

In the future, Luculent will continue to increase R&D investment, enhance its core competitive advantages, and join hands with leading biotechnology enterprises, research institutions, and upstream and downstream enterprises in the industrial chain to jointly create an open, shared, forward-looking, and interdisciplinary new ecology of synthetic biology intelligent manufacturing industry.